Ipamorelin dosage: what was given, to whom, by which route

Before the details

This page lists the ipamorelin doses that appear in real studies — what researchers gave, to which species, and how. It is a record, not a recommendation. There is no approved human dose, because the compound was never approved, and the one human efficacy trial used an intravenous hospital protocol that did not work ^[3].

A few facts orient everything else. Ipamorelin clears fast: a roughly two-hour half-life in people, with a single growth-hormone pulse about 40 minutes after dosing ^[2]. It is given by injection — intravenous in the human studies, mostly subcutaneous in research-use settings. It is not orally active. Where community "stack" protocols are mentioned below, they are described as what people report doing, clearly flagged as having no controlled-trial basis — not as instructions.

Doses used in human studies

Two human datasets define the record. The 1999 pharmacokinetic study administered five single 15-minute intravenous infusions ranging from 4.21 to 140.45 nmol/kg, to eight healthy men per dose level ^[2]. The kinetics were dose-proportional across that range, establishing the linear pharmacokinetics and ~2-hour half-life ^[2].

The 2014 Phase 2 ileus trial used a fixed clinical regimen: 0.03 mg/kg intravenously twice daily, on postoperative days 1 through 7 or until discharge, in 114 bowel-resection patients ^[3]. That is the only repeated-dosing human protocol in the published literature — and it is a short, hospital-administered, intravenous course that missed its efficacy endpoint ^[3]. Neither human study supports any subcutaneous home-use regimen, because none was tested.

Doses used in animal studies

Animal work spans a wider dose range and several routes. In the rat bone-growth study, subcutaneous ipamorelin was given at 18, 90, and 450 microg/day, divided three times daily over 15 days ^[4]. A separate rat bone-mineral study used 0.5 mg/kg/day delivered continuously by osmotic minipump over 12 weeks, and rat ileus work used 0.1 to 1 mg/kg intravenously, repeated four times daily.

The most recent animal study, the 2024 ferret cachexia model, used 1 to 3 mg/kg intraperitoneally ^[5]. Across species the routes studied include intravenous (human pharmacokinetics and trials; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in research-use settings), intranasal (rodent pharmacokinetics, roughly 20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral absorption.

How much cjc-1295 ipamorelin should i take

There is no answer to how much cjc-1295 ipamorelin should i take that comes from a controlled human trial — none has ever tested the combination, so any number circulating online is community practice, not evidence ^[11]. The only repeated-dosing human ipamorelin data come from a hospital intravenous protocol for a different purpose that failed its endpoint ^[3], and the only other human data are acute single intravenous infusions used to measure pharmacokinetics ^[2]. Recent reviews classify ipamorelin as investigational and recommend confining it to research protocols ^[16]. This site describes what was studied; it does not provide a dose to take.

Half-life and timing

The pharmacokinetic picture is the most precise part of the dosage record. In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth-hormone response is not sustained — it is a single discrete pulse peaking around 40 minutes after dosing ^[2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6.

That short half-life is why the half-life page treats timing as central to both detection windows and dosing patterns. It is also why community protocols favor frequent dosing — though, again, those patterns have no controlled-trial basis.

How to reconstitute cjc-1295 ipamorelin 5mg

On how to reconstitute cjc-1295 ipamorelin 5mg: ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction — and because research-grade material from unregulated suppliers carries no quality assurance, peptide identity, purity, and sterility are unverified ^[17]. This site does not provide preparation or injection instructions.

Why the combination protocols lack a basis

Research-use "stack" protocols pair ipamorelin with CJC-1295 on subcutaneous schedules. These have no peer-reviewed human dosing basis and must be read as anecdotal, not recommended. The combination's rationale is each agent's separate pharmacology — complementary mechanisms raising growth hormone ^[1] — not any trial of the pair ^[11]. The honest dosage summary for ipamorelin is narrow: two human studies, both intravenous, one acute and one a failed 7-day course ^[2][3]; everything beyond that is animal data or community practice.